While one study found no correlation between the presence of anti-Ro52 antibodies and Raynaud’s phenomenon, sclerodactyly, digital ulcers, gangrene, calcinosis cutis, telangiectasia, or esophageal dysmotility [63], anti-Ro52 antibody is predictor of poor survival in SSc [64]. This evidence concerns the gene TRIM21 and systemic sclerosis.